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Immunohistochemical Detection of
Aflatoxin B1-DNA Adducts and Hepatitis
B Virus Antigens in Hepatocellular
Carcinoma and Nontumorous Liver
Tissue
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Chen, Ling-Ling Hsieh,' Chue-Shue Lee,2 Bahram
Haghighi,"3 Guang-Yang Yang,' Lian-Wen Wang,'
and Mark Feitelson4
Monoclonal antibodies recognizing thestableimidazole ring-opened formofthe majorN7-guanineaflatoxinB,-DNA
adducthavebeenusedincompetitiveenzyme-linkedimmunosorbentassays(ELISA)andindirectimmunofluorescence
assaystoquantitateadductlevelsinlivertissue. MethodsweredevelopedinAFBI-treatedanimals, thenappliedtopaired
tumorandnontumorlivertissuesofhepatoceliularcarcinomapatientsfrom Taiwan. Anavidin-biotincomplexstaining
methodwasalsousedforofthedetectionofhepatitisBsurface(HBsAg)andX(HBxAg)antigensinliversections. Atotal
of8 (30%) hepatocellular carcinoma (HCC) samplesand7(26%) adjacent nontumorlivertissuesamplesfromTaiwan
werepositiveforAFB,-DNAadducts. ForHEsAg, 10(37%)HCCsamplesand22(81%)adjacentnontumorousliversamples
werepositive,and9(33%)HCCsamplesandU (41%)adjacentnontumorliversunpleswereHBxAgpositive.Noassociation
withAFBI-DNAadductswasobservedforHBsAgandHBxAg. Thesemethodsshouldbeuseful indeterminingtherole
ofexposure in the induction ofHCC inTaiwan.
Introduction
Hepatocellular carcinoma (HCC) is oneofthemajor cancers
in the world (1) and the leading cancer for males in Taiwan,
wherehepatitis Bvirus (HBV) ishyperendemic (2). Hepatitis B
virus has been established as one ofthe most important deter-
minants ofHCC; however, documented, independent risk fac-
tors ofHCC includeaflatoxin exposure, hepatitis Cvirus infec-
tion, alcohol drinking, cigarette smoking, and familial tenden-
cy (3-6).
To better determine exposure to aflatoxin at the individual
level, monoclonal antibodies have been developed against the
stable imidazole ring-opened formofthemajorguanineadduct
ofaflatoxin B1 (AFB,) (7,8). Antibodies recognizingthisadduct
were used in acompetitiveenzyme-linked immunosorbent assay
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(ELISA) to-quantitate DNA adducts in liver DNA ofanimals
treated with AFBI and in human liver tissue ofHCC patients
fromTaiwan(9). Intheseinitialstudiesonninepatients, adducts
weredetected inalltumorsamplesand in25% ofnormal adja-
centtissues. Adductlevelsrangedfrom 1.2to3.5/106nucleotides.
Immunohistochemical Detection of
Adducts in Rat Liver
Forthedevelopmentofimmunohistochemcial methods forthe
detectionofAFBI-DNAadducts, ratsweretreatedwithseveral
dosesofAFBI rangingfrom 1 to3.75mg/kgandsacrificedafter
2hr(10). Frozenliversectionsfixedin70% ethanol weretreated
with 15mMNa2CO3/30mMNaHCO3(pH9.6)for2hratroom
temperature to ring open the guanine adducts. Liver sections
werethentreatedwithRNAse(100Ztg/mL)at37°Cfor 1 hr, with
proteinase K (10ttg/mL) at room temperature for 10 min, and
with 50 mM NaOH in 40% ethanol for 30 sec at room tem-
peraturetodenaturetheDNA. Slideswerethenincubatedwith
antibody6A10at37°Cfor45 minandwithgoatanti-mouseIgG
conjugated with fluoresceinisothiocyante (FITC) at37°C for45
min. They were stained with 4',6-diamidino-2-phenylindole
dihydrochloride (DAPI; 1 mg/mL) at37°C for45 min to allow
visualization ofthe nuclei.SANTELLA ETAL.
Combined FITC-DAPI staining was observed with a Nikon
Optiphotmicroscope (Nikon, Tokyo). Photographs weretaken
with KodachromeASA400 slide filmandfluorescence intensi-
ty ofnuclei measured from the color slides using a Molecular
Dynamics 300Adensitometer(MolecularDynamics, Sunnyvale,
CA). The fluorescence intensity ofeachnucleus inagiven liver
sectionwasdeterminedbythedifference influorescence inten-
sity between the nucleus and its surrounding cytoplasm, as
described (10).
FITC staining was localized to the nuclei in animals treated
with 2.5 mg/kg (Fig. 1). Sections froma control, untreated rat
were negative, as werethe additional controls ofsections from
a treated rat incubated with DNAse before staining or stained
with antiserum that had been preabsorbed with AFBI-DNA.
Quantitativedeterminationofrelativefluorescence indicated a
dose-reponse relationship between fluorescence intensity and
doseofAFB,. DNA wasalso isolatedfromlivertissueand ad-
duct levels determined by competitive ELISA with antibody
A
B
FIGURE 1. Indirect immunofluorescence stainingforimidazolering-openedAFBI-DNAadductswithantibody6A10andgoatanti-mouseIgG-fluorescein isothio-
cyanate of(A) a liver section from a rat treated with 2.5 mg/kg AFBI and (H) a human liversection from Taiwan.
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Table 1. Indirect immunotluorescence assay ofAFB,-DNAadductsand immunoperoxidase stainingofHBsAgand HBxAgin HCC tumor
and nontumorlivertissuesfromTaiwan.
Indirect immunofluorescence HBsAg/HBxAg
Country of Type ofliver + - ++ +1- -1+ -I-
origin tissue No. % No. % No. % No. % No. % No. % Total
Taiwan Nontumor 7 26 20 74 11 41 11 41 5 18 27
Tumor 8 30 19 70 5 19 5 19 4 15 13 48 27
United States Noncancer 5 100 5 100 5
HCC I 100 1 100 I
Other tumors 2 100 2 100 2
Abbreviations: AFBI, aflatoxin B,; HBsAg, hepatitis B virus surface antigen; HBxAg, hepatitis B virus X antigen; HCC, hepatocellular carcinoma.
6A10(9). Therewasagoodcorrelation (r = 0.61,p < 0.05)be-
tween adduct levels determined by densitometric scanning of
tissuesectionsandELISAquantitationofanadductsonisolated
DNA. Inaddition, analternativemethodofanalysiswasusedto
confirm the immunological data. Quantitation ofadduct levels
by measurement offluorescence spectra ofliver DNA isolated
fromthetreatedanimalscorrelated (r = 0.78,p < 0.01)withthe
densitometric scanning ofimmunohistochemically stained sec-
tions oflivertissue.
Immunohistochemical Detection of
Adducts in Human Liver
The indirect immunofluorescence method was recently ap-
plied to the detection ofAFB,-DNA adducts in frozen liver
tissue sections fromTaiwan(11). Atotalof27pairsofsurgical-
lyremovedtumorandadjacentnontumorlivertissuesfromHCC
patients were collected in the National Taiwan University
Hospital. Figure lB shows a liver section positive for AFB,-
DNAadducts. Eight(30%)ofthetumorand seven(26%) ofthe
nontumor liver tissues of twenty-seven HCC patients from
Taiwan haddetectable levels ofAFB,-DNA adducts (Table 1).
EightliversamplesfromtheUnitedStates, including oneHCC
obtainedthroughtheU.S.NationalCancerInstituteCooperative
Human Tissue Network, werealso tested, butno adducts were
detectable by indirect immunofluorescence.
Hepatitis BsurfaceandXantigen (HBsAgandHBxAg) were
detected with an avidin-biotin complex staining method (11).
Bothpositiveandnegativestaining forHBsAgandHBxAgwere
observed intheHCC tissues. Forthe27 nontumorlivertissues,
41% werepositive forbothHBsAgandHBxAg, 41% forHBsAg
alone, 0% forHBxAgalone, and 18% forneitherantigen(Table
1). Thecorrespondingfrequencies were 19, 19, 15, and48% for
HCC tissues. ThesingleU.S. HCC samplewaspositiveforboth
HBsAg and HBxAg. Allother U.S. samples werenegative.
Table 2 gives the results ofcombining the statusofHBV an-
tigensandAFB1-DNAadductsinpairedHCCandadjacentnon-
tumor livertissues foreachTaiwanpatient. Although24(89%)
ofHCCpatientshadHBsAgand/orHBxAgineitherHCC orad-
jacentnontumorlivertissues, 14(52%)haddetectablelevelsof
AFB,-DNA adducts in their HCC and/or adjacent nontumor
livertissues. Therewere 13 HCCpatientswhowerepositivefor
bothHBVantigensandAFB -DNAadducts; 11 werepositivefor
HBVantigensbutnotforadducts; 1 waspositiveforadductson-
ly; and 2 were negative for both HBV antigens and adducts.
There was nosignificantassociationbetweenthecarrier status
ofHBsAgand/orHBxAgandthedetectablelevelofAFB,-DNA
adducts.
Table2. PresenceofhepatitisBvirusantigensandAFB,-DNA adducts in
pairedtumor and nontumor tissueof27HCC cases inTaiwan.
Hepatitis B antigens
AFB,-DNA Positive Negative Total
adduct No. % No. % No. %
Positive 13 48 1 4 14 52
Negative 11 41 2 7 13 48
Total 24 89 3 11 27 100
Abbreviations: AFBI, aflatoxin B,; HCC, hepatocellular carcinoma.
Discussion
These studies demonstrate that quantitative immunohisto-
chemical methodscanbeusedtomonitorexposuretoaflatoxin
B1 bymeasurementofDNAadductsinlivertissuewhenpresent
atlevelshigherthan 1/106nucleotides. Samplesobtainedduring
surgery for HCC contained adducts at levels known to induce
tumors in animals (12). Although these methods may not be
useful forroutinemonitoring ofhealthy individuals, they arean
important tool in understanding the role ofAFB, in HCC. The
resultspresentedheresuggestthatAFBI maybeinvolvedinthe
developmentofHCC in Thiwan. Bothadductsandviralantigens
arepresentinthetumorousandnontumoroustissuesintheliver
ofmost HCCpatients, buttheir relationship is not statistically
significant. Theseresultsarecompatiblewiththeconclusion that
HBVandAFB, donotactsynergistically inthegenesisofHCC,
butfurtherinvestigationwillbenecessarytodefinetherelation-
shipbetweenHBVandAFB1. Wearecurrentlyimplementing a
case-controlstudyofAFB,-DNAtodeterminewhetheradduct
levelsarehigherinHCCpatients. Thisapproachshouldprovide
more directevidence forthe roleofaflatoxin in HCC.
Thismanuscriptwaspresented asaposterattheConferenceonBiomonitor-
ing and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that washeld in Kailua-Kona, Hawaii, 26
October-I November 1991.
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